MEN1 mutations mediate clinical resistance to menin inhibition-Reference-Cited by-同舟云学术

MEN1 mutations mediate clinical resistance to menin inhibition

Published:2023-03-15 Issue:7954 Volume:615 Page:913-919
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Perner Florian,Stein Eytan M.,Wenge Daniela V.^ORCID,Singh Sukrit,Kim Jeonghyeon,Apazidis Athina,Rahnamoun Homa^ORCID,Anand Disha,Marinaccio Christian,Hatton Charlie,Wen Yanhe,Stone Richard M.^ORCID,Schaller David,Mowla Shoron,Xiao Wenbin^ORCID,Gamlen Holly A.^ORCID,Stonestrom Aaron J.^ORCID,Persaud Sonali,Ener Elizabeth^ORCID,Cutler Jevon A.,Doench John G.^ORCID,McGeehan Gerard M.,Volkamer Andrea,Chodera John D.^ORCID,Nowak Radosław P.,Fischer Eric S.^ORCID,Levine Ross L.^ORCID,Armstrong Scott A.^ORCID,Cai Sheng F.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

https://www.nature.com/articles/s41586-023-05755-9.pdf

Reference26 articles.

1. Rodrigues, C. P., Shvedunova, M. & Akhtar, A. Epigenetic regulators as the gatekeepers of hematopoiesis. Trends Genet. 37, P125–P142 (2021).

2. Uckelmann, H. J. & Armstrong, S. A. Chromatin complexes maintain self-renewal of myeloid progenitors in AML: opportunities for therapeutic intervention. Stem Cell Rep. 15, 6–12 (2020).

3. Yokoyama, A. et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123, 207–218 (2005).

4. Yokoyama, A. & Cleary, M. L. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 14, 36–46 (2008).

5. Kuhn, M. W. et al. Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia. Cancer Discov. 6, 1166–1181 (2016).

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations;Expert Review of Hematology;2024-09-13

2. A menin-KMT2A inhibitor to overcome resistance;Blood;2024-09-12

3. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias;Blood;2024-09-12

4. Lessons learned during the journey of data: from experiment to model for predicting kinase affinity, selectivity, polypharmacology, and resistance;2024-09-10

5. In vivo CRISPR screens identify a dual function of MEN1 in regulating tumor–microenvironment interactions;Nature Genetics;2024-09